Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Pradigastat sodium
Cat. No.:
OB0425LY-234
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Pradigastat sodium is a effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with anti-obesity and anti-diabetic effects.
Synonyms:
956136-98-4; Lcq-908 sodium salt; Lcq-908a; Sodium 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetate
CAS No.:
956136-98-4
Compound CID:
53387034
Formula:
C25H23F3N3NaO2
Formula Weight:
477.45
Specification
Target:
Acyltransferase; BCRP; OAT
Pathway:
Metabolic enzyme/Protease; Membrane transporter/Ion channel
Storage:
Storage at -20°C.
Applications:
Pradigastat sodium can be used to study diseases associated with abnormal triglyceride metabolism.
